Journal Mobile Options
Table of Contents
Vol. 13, No. 2, 1993
Issue release date: 1993
Am J Nephrol 1993;13:115–123
Clinical Study

Bone Mineral Density in Patients with End-Stage Renal Failure

Gabay C.a · Ruedin P.a · Slosman D.b,c · Bonjour J.-P.b · Leski M.a · Rizzoli R.b
aDivision of Nephrology, bDivision of Clinical Pathophysiology (WHO Collaborating Centre for Osteoporosis and Bone Disease), and cDivision of Nuclear Medicine, University Hospital, Geneva, Switzerland


Renal osteodystrophy is a well-recognized complication of chronic renal failure (CRF) and is associated with a marked morbidity. Bone mineral density (BMD) has been shown to be the best predictor of fracture risk in different circumstances. In this cross-sectional study, we measured BMD using dual photon absorptiometry at three skeletal sites of functional importance such as the lumbar spine (LS), the femoral shaft (FS) and the femoral neck (FN) in 106 patients with end-stage renal failure (11 predialysis patients and 95 patients on maintenance dialysis). These skeletal sites are characterized by various relative amounts of trabecular and cortical bone. The results indicate that decreased bone mass was detectable in all skeletal sites before the beginning of dialysis and that BMD was negatively related to dialysis duration in LS and FS. Nevertheless, the deleterious effects of renal osteodystrophy were more pronounced at the FS level, where cortical bone is predominant. A separate analysis of BMD in both sexes revealed that females presented a more important bone loss in both cortical and trabecular bone than males. We did not find any significant difference in BMD at the three measured sites between patients on continuous ambulatory peritoneal dialysis and on regular hemodialysis. This study emphasizes the need to pay more attention to the prevention of bone loss in patients on CRF before the start of dialysis therapy, and to the fact that the female population might display a more pronounced susceptibility to bone loss.

 goto top of outline Author Contacts

Dr. P. Ruedin, MD, Division of Nephrology, University Hospital, 24 rue Micheli-du-Crest, CH-1211 Geneva 14 (Switzerland)

 goto top of outline Article Information

Received: August 29, 1992
Accepted: January 25, 1993
Published online: October 28, 2008
Number of Print Pages : 9

 goto top of outline Publication Details

American Journal of Nephrology

Vol. 13, No. 2, Year 1993 (Cover Date: 1993)

Journal Editor: Bakris G. (Chicago, Ill.)
ISSN: 0250–8095 (Print), eISSN: 1421–9670 (Online)

For additional information:

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.